Clinical factors associated with composition of lung microbiota and important taxa predicting clinical prognosis in patients with severe community-acquired pneumonia
© 2021. Higher Education Press..
Few studies have described the key features and prognostic roles of lung microbiota in patients with severe community-acquired pneumonia (SCAP). We prospectively enrolled consecutive SCAP patients admitted to ICU. Bronchoscopy was performed at bedside within 48 h of ICU admission, and 16S rRNA gene sequencing was applied to the collected bronchoalveolar lavage fluid. The primary outcome was clinical improvements defined as a decrease of 2 categories and above on a 7-category ordinal scale within 14 days following bronchoscopy. Sixty-seven patients were included. Multivariable permutational multivariate analysis of variance found that positive bacteria lab test results had the strongest independent association with lung microbiota (R2 = 0.033; P = 0.018), followed by acute kidney injury (AKI; R2 = 0.032; P = 0.011) and plasma MIP-1β level (R2 = 0.027; P = 0.044). Random forest identified that the families Prevotellaceae, Moraxellaceae, and Staphylococcaceae were the biomarkers related to the positive bacteria lab test results. Multivariable Cox regression showed that the increase in α-diversity and the abundance of the families Prevotellaceae and Actinomycetaceae were associated with clinical improvements. The positive bacteria lab test results, AKI, and plasma MIP-1β level were associated with patients' lung microbiota composition on ICU admission. The families Prevotellaceae and Actinomycetaceae on admission predicted clinical improvements.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Frontiers of medicine - 16(2022), 3 vom: 24. Juni, Seite 389-402 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Du, Sisi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7-category ordinal scale |
|---|
| Anmerkungen: |
Date Completed 22.07.2022 Date Revised 25.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11684-021-0856-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328474479 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328474479 | ||
| 003 | DE-627 | ||
| 005 | 20231225203009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11684-021-0856-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM328474479 | ||
| 035 | |a (NLM)34302613 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Du, Sisi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical factors associated with composition of lung microbiota and important taxa predicting clinical prognosis in patients with severe community-acquired pneumonia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.07.2022 | ||
| 500 | |a Date Revised 25.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. Higher Education Press. | ||
| 520 | |a Few studies have described the key features and prognostic roles of lung microbiota in patients with severe community-acquired pneumonia (SCAP). We prospectively enrolled consecutive SCAP patients admitted to ICU. Bronchoscopy was performed at bedside within 48 h of ICU admission, and 16S rRNA gene sequencing was applied to the collected bronchoalveolar lavage fluid. The primary outcome was clinical improvements defined as a decrease of 2 categories and above on a 7-category ordinal scale within 14 days following bronchoscopy. Sixty-seven patients were included. Multivariable permutational multivariate analysis of variance found that positive bacteria lab test results had the strongest independent association with lung microbiota (R2 = 0.033; P = 0.018), followed by acute kidney injury (AKI; R2 = 0.032; P = 0.011) and plasma MIP-1β level (R2 = 0.027; P = 0.044). Random forest identified that the families Prevotellaceae, Moraxellaceae, and Staphylococcaceae were the biomarkers related to the positive bacteria lab test results. Multivariable Cox regression showed that the increase in α-diversity and the abundance of the families Prevotellaceae and Actinomycetaceae were associated with clinical improvements. The positive bacteria lab test results, AKI, and plasma MIP-1β level were associated with patients' lung microbiota composition on ICU admission. The families Prevotellaceae and Actinomycetaceae on admission predicted clinical improvements | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 7-category ordinal scale | |
| 650 | 4 | |a Prevotellaceae | |
| 650 | 4 | |a clinical improvements | |
| 650 | 4 | |a lung microbiota | |
| 650 | 4 | |a severe community-acquired pneumonia | |
| 650 | 7 | |a Chemokine CCL4 |2 NLM | |
| 650 | 7 | |a RNA, Ribosomal, 16S |2 NLM | |
| 700 | 1 | |a Wu, Xiaojing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Binbin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yimin |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Lianhan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Yudi |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Donghao |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Naicong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhibo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chunlei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xinmeng |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Zhujia |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Xiaohui |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Binghuai |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yingmei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Qingyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Bin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers of medicine |d 2011 |g 16(2022), 3 vom: 24. Juni, Seite 389-402 |w (DE-627)NLM203731344 |x 2095-0225 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:3 |g day:24 |g month:06 |g pages:389-402 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11684-021-0856-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 3 |b 24 |c 06 |h 389-402 | ||